The reverse merger announced Wednesday morning between Magenta Therapeutics and privately-held Dianthus Therapeutics, which will take over the Nasdaq spot and push forward its complement pathway drug candidates, highlighted the growing field of such financing moves as dozens of public biotechs search for ways to appease shareholders and as private startups trudge toward Wall Street in an unforgiving IPO environment. At least 20 public biotech companies have flashed the red lights in recent months, saying they are searching for some sort of way out, whether via a merger, sale or other transaction, per a tally of Endpoints News stories so far this year.
Read the full article: Reverse Mergers Say Hey as Biotechs Trade Low, Hunt for Alternatives and Launch Few IPOs //
Source: https://endpts.com/magenta-dianthus-deal-part-of-a-larger-biotech-reverse-merger-train